Different reverse remodelling between left ventricle and right ventricle in fulminant heart failure due to giant cell myocarditis: a case report.

Case report Endocardium biopsy Giant cell myocarditis Heart failure

Journal

European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 22 01 2021
revised: 02 03 2021
accepted: 06 05 2021
entrez: 13 9 2021
pubmed: 14 9 2021
medline: 14 9 2021
Statut: epublish

Résumé

Giant cell myocarditis (GCM) is a rare cause of fulminant heart failure (HF). The most common presentation is progressive hemodynamic deterioration, and a few cases present with idiopathic complete atrioventricular block (cAVB). The prognosis of GCM is poor, and GCM patients usually die of HF and ventricular arrhythmia unless cardiac transplantation is performed. Few reports have described the effects of treatments such as immunosuppression and detailed reverse remodelling in GCM patients. A 69-year-old female presented with cAVB. Transvenous pacemaker was implanted via the left subclavian vein. One and a half months later, she exhibited left ventricular dyssynchrony and lower left ventricular ejection fraction (LVEF), resulting in hospitalization for HF. She received cardiac resynchronization therapy; however, this had no apparently positive effects on her cardiac function. To investigate the cause of the lower LVEF, an endomyocardial biopsy was taken from the right ventricular septum. She was diagnosed with GCM and immediately received immunosuppression therapy with prednisolone and ciclosporin. This resulted in the functional recovery of the right ventricle; on the other hand, the left ventricle had still not recovered based on transthoracic echocardiography. Fortunately, she successfully recovered from severe HF without recurrence. This is a case of fulminant HF due to GCM which initially presented as cAVB. Moreover, this case demonstrates the quite difference of the functional recovery between the left ventricle and the right ventricle with immunosuppression therapy.

Sections du résumé

BACKGROUND BACKGROUND
Giant cell myocarditis (GCM) is a rare cause of fulminant heart failure (HF). The most common presentation is progressive hemodynamic deterioration, and a few cases present with idiopathic complete atrioventricular block (cAVB). The prognosis of GCM is poor, and GCM patients usually die of HF and ventricular arrhythmia unless cardiac transplantation is performed. Few reports have described the effects of treatments such as immunosuppression and detailed reverse remodelling in GCM patients.
CASE SUMMARY METHODS
A 69-year-old female presented with cAVB. Transvenous pacemaker was implanted via the left subclavian vein. One and a half months later, she exhibited left ventricular dyssynchrony and lower left ventricular ejection fraction (LVEF), resulting in hospitalization for HF. She received cardiac resynchronization therapy; however, this had no apparently positive effects on her cardiac function. To investigate the cause of the lower LVEF, an endomyocardial biopsy was taken from the right ventricular septum. She was diagnosed with GCM and immediately received immunosuppression therapy with prednisolone and ciclosporin. This resulted in the functional recovery of the right ventricle; on the other hand, the left ventricle had still not recovered based on transthoracic echocardiography. Fortunately, she successfully recovered from severe HF without recurrence.
DISCUSSION CONCLUSIONS
This is a case of fulminant HF due to GCM which initially presented as cAVB. Moreover, this case demonstrates the quite difference of the functional recovery between the left ventricle and the right ventricle with immunosuppression therapy.

Identifiants

pubmed: 34514299
doi: 10.1093/ehjcr/ytab214
pii: ytab214
pmc: PMC8422336
doi:

Types de publication

Case Reports

Langues

eng

Pagination

ytab214

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Circulation. 2020 Feb 11;141(6):e69-e92
pubmed: 31902242
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
Open Heart. 2018 Jan 20;5(1):e000667
pubmed: 29387425
Circ Heart Fail. 2013 Jan;6(1):15-22
pubmed: 23149495
Eur Heart J. 2008 Jul;29(13):1696; author reply 1696-7
pubmed: 18456711
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Mayo Clin Proc. 1999 Dec;74(12):1221-6
pubmed: 10593350
Am J Cardiol. 2008 Dec 1;102(11):1535-9
pubmed: 19026310
ESC Heart Fail. 2020 Feb;7(1):315-319
pubmed: 31872976
J Am Coll Cardiol. 1995 Apr;25(5):1143-53
pubmed: 7897128
N Engl J Med. 1997 Jun 26;336(26):1860-6
pubmed: 9197214
Circ Res. 2019 May 24;124(11):1568-1583
pubmed: 31120823
Am J Cardiol. 2015 Jun 15;115(12):1733-8
pubmed: 25882774
Eur Heart J Cardiovasc Imaging. 2015 Jan;16(1):47-52
pubmed: 25187607

Auteurs

Hiroaki Yokoyama (H)

Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Okamoto 1370-1, Kamakura 247-8533, Japan.

Masashi Yamaguchi (M)

Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Okamoto 1370-1, Kamakura 247-8533, Japan.

Kazuki Tobita (K)

Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Okamoto 1370-1, Kamakura 247-8533, Japan.

Shigeru Saito (S)

Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Okamoto 1370-1, Kamakura 247-8533, Japan.

Classifications MeSH